>This sounds like the FDA will only allow VRTX to test for 12 weeks only and are not willing to take a chance for it to be tested longer without further the six month animal tox studies.<
This is not in dispute—VRTX concedes that they cannot give patients VX-950 for longer than 12 weeks until they have results from the six-month tox studies this fall.
Given that VX-950 treatment is limited to 12 weeks until this fall, the question remains as to why VRTX is testing 36 weeks of interferon/ribavirin treatment without VX-950 following 12 weeks of treatment with VX-950. The company’s rationale, which I posed in the prior message, apparently did not ring true for some of the analysts on the CC. Regards, Dew
Market Data 
Markets 
AI
